Commerce Bank Decreases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Commerce Bank decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 55.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,934 shares of the medical device company’s stock after selling 23,278 shares during the quarter. Commerce Bank’s holdings in DexCom were worth $1,269,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Capital Insight Partners LLC raised its position in shares of DexCom by 2.5% during the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after purchasing an additional 90 shares during the period. HM Payson & Co. raised its holdings in DexCom by 6.0% during the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock valued at $247,000 after acquiring an additional 100 shares during the period. Clear Creek Financial Management LLC lifted its position in shares of DexCom by 4.2% in the second quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock valued at $336,000 after acquiring an additional 120 shares in the last quarter. SeaCrest Wealth Management LLC lifted its position in shares of DexCom by 3.6% in the second quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock valued at $501,000 after acquiring an additional 152 shares in the last quarter. Finally, Securian Asset Management Inc. boosted its stake in shares of DexCom by 0.7% in the second quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock worth $2,593,000 after acquiring an additional 161 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DexCom stock opened at $72.83 on Monday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a market capitalization of $28.45 billion, a PE ratio of 43.61, a P/E/G ratio of 2.28 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The company has a 50-day simple moving average of $70.61 and a two-hundred day simple moving average of $89.28.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The trade was a 0.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,431 shares of company stock worth $399,319 in the last 90 days. 0.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on DXCM shares. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Stifel Nicolaus raised their target price on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. JPMorgan Chase & Co. upped their target price on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Finally, Raymond James decreased their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.